This document advertises an upcoming conference on pharmaceutical portfolio and product life-cycle management taking place from June 29-30, 2011 in London. It provides details on registration discounts, key speakers from major pharmaceutical companies, and the conference agenda covering topics such as portfolio management strategies, risk analysis, partnerships and licensing, and life-cycle planning. A pre-conference workshop on portfolio planning tools is also advertised for June 28.

1. REGISTER BY 28th FEBRUARY AND RECEIVE A £300 DISCOUNT
REGISTER BY 31ST MARCH AND RECEIVE A £100 DISCOUNT
SMi present their 6th annual conference on...
Pharmaceutical Portfolio &
Product Life-Cycle Management
Wednesday 29th – Thursday 30th June 2011
Holiday Inn Bloomsbury, London
KEY SPEAKERS INCLUDE
Ulrich Betz
Director, Department Head Centre of Innovation,
Merck Serono
Tony Ellery
President, Ellery Pharma Consulting, Former Global Head
LCM in Portfolio Management
Novartis
Alessio Merlin
Director Strategic Planning
Bayer
Tim Harris
Director Respiratory & Immuno-inflammation
Portfolio Management
GSK
Getting the most out of your product
Marie Bernasconi
Global Program Team Director
portfolio becomes paramount as Novartis
budgets become more restricted. This Carmel Egan
Vice President, Project Management
conference provides a unique chance to Eli Lilly
utilise the experiences of top level
AT THIS CONFERENCE YOU WILL
managers in developing successful • Discuss other’s approaches to fully integrated portfolio
and PLCM management
portfolio and product life-cycle • Learn of the latest EU patent regulatory guidance
• Analyse the most effective risk mitigation strategies
management strategies. • Debate the merits and drawbacks of portfolio out licensing
• Network with our expert speaker line up
PLUS A HALF-DAY POST-CONFERENCE WORKSHOP
Tuesday 28th June 2011, Holiday Inn Bloomsbury, London
Tools and Techniques for Optimal Drug Development Portfolio Planning:
Portfolio Selection, Resource Allocation, and Risk Mitigation
Workshop Leader: Vladimir Shnaydman, President, ORBee Consulting
1.30pm-5.30pm
www.pharma-portfolio.com
Register online and receive full information on all of SMi’s conferences
Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

2. Pharmaceutical Portfolio & Product
Life-Cycle Management
Day One | Wednesday 29th June 2011
www.pharma-
8.30 Registration and coffee 2.10 Where is the strategy in the strategy?
• What does portfolio strategy mean in early phase?
9.00 Chairman's opening remarks
• Aligning Discovery, Clinical, Market Access and Commercial
Tony Ellery, President, Ellery Pharma Consulting, Former Global
• Integrating Value Proposition in early phase development:
Head LCM in Portfolio Management, Novartis
biomarkers, PROs, PE assessment
9.10 Linking portfolio management with business strategy Mike Rea, Chief Executive Officer, IDEA Pharma
• Developing an integrated approach to portfolio management
• Closing the gap between theory and practise 2. 50 Holistic portfolio management at Bayer Schering Pharma
• Adapting to the organisational culture
• Key elements of portfolio management approach
• Tips for successful integration
Hans Hoogkamer, Business and Science Affairs, Actelion • Decision analysis process at R&D milestones
Pharmaceuticals • Bridging strategy claims and operational reality
Alessio Merlin, Director Strategic Planning, Bayer
9.50 Integrated portfolio modelling (early to late) in support of strategy
• Overview of the models, processes and outputs
3.30 Afternoon Tea
• Different models for different insights
• Gaining credibility: linking models with strategy
• Learnings and challenges 3.50 Portfolio Management – It’s not about the numbers
Michael O'Grady, Portfolio-Analysis Manager, GlaxoSmithKline • Why Portfolio Management should not just focus on probabilities
and NPVs
10.30 Morning Coffee • How to integrate the context into the thinking
• The fully integrated strategic portfolio
10.50 Portfolio management: Integrated approaches to R&D
• Aligning portfolio & productivity with corporate strategy Tim Harris Director, Respiratory & Immuno-inflammation Portfolio
• How to identify, select and manage a new project from R&D and Management, GSK
drive up performance
• Informed and effective resource allocation 4.30 Managing a mixed portfolio: Making key decisions at the science,
Mellor Hennessy, Global Portfolio Strategist, AstraZeneca*
project, resource, and governance level
• Managing diverse portfolios comprised of small chemical
11.30 Tailoring R&D portfolio management to the needs of your company
• The ‘must-haves’ and the ‘optionals’ in R&D portfolio management structures and a range of complex biomolecules
• Requirements in companies of different sizes • Providing portfolio governance from discovery through
• Managing the portfolio across the discovery/development interface commercialization, decision making and prioritization
• Effective portfolio risk management • The factors involved in the reliable delivery of a blended portfolio
Kerstin Bode-Greuel, Lecturer, University of Essen/PME Institute
comprised of 30%-40% biomolecules
12.10 Networking lunch • Lilly’s approach to achieve improved patient outcomes
• Fully utilising the external universe of talent and capabilities to
1.30 Project and portfolio risk analysis optimally manage a complex portfolio
• Measuring Project and Portfolio Risk Carmel Egan, Vice President Project Management, Eli Lilly
• Portfolio simulations. Monte Carlo analysis
• Correlated risks in development portfolios
5.10 Chairman's Closing Remarks and Close of Day One
• Risk mitigation
Kimber Hardy, Head of Valuation and Analysis, Portfolio Management, Tony Ellery, President, Ellery Pharma Consulting, Former Global
Merck Serono Head LCM in Portfolio Management, Novartis
*Subject to confirmation
Register online at www.pharma-portfolio.com • Alternatively fax
Who should attend: Past attendee breakdown:
Heads, Directors, Senior Directors, Managers, Vice Presidents and
Leaders in the following areas:
UK
• Portfolio Management • Lifecycle Management
• Portfolio Development • Product Strategy USA
• Portfolio Coordinator • Product development Europe
• Business Development • Programme management
Other
• Project management • Strategic Marketing
• Valuation and Analysis • Brand development
• Strategic Marketing • Generics
Supported by

3. Pharmaceutical Portfolio & Product
Life-Cycle Management
-portfolio.com Day Two | Thursday 30th June 2011
8.30 Re-registration and coffee 12.10 Networking lunch
9.00 Chairman's opening remarks 1.30 Life-cycle Management - Applied case study
Tony Ellery, President, Ellery Pharma Consulting, Former Global Head • Early stage LCM: How to maximize value of products across lifecycle,
LCM in Portfolio Management, Novartis when to implement and execute
• Experiences of being close to the market
9.10 Partnerships, alliances and collaborations: Achieving successful • Lessons to be learned
portfolio management
Marie Bernasconi, Global Program Team Director, Novartis
• Successful approaches
• Case studies in collaborative portfolio development
2.10 Early stage strategies and intellectual property
• Establishing then maintaining a mutually beneficial relationship
• "Publish and be Damned!" (Duke of Wellington) - Patent issues in
Arif Shivji, World Wide Business Development Director, Pfizer
early stages
• Patents as tools to assist portfolio management
9.50 PANEL DISCUSSION:
• Patents as taskmasters in product lifecycles
In-house portfolio vs. in-licensing/out-licensing strategies
• Big Pharma R&D (Research & Development) vs. Big Pharma S&D • "What's in a Name?" (Shakespeare) - Naming issues in early stages
(Search & Development) • Trademarks considerations in product portfolios
• Different approaches and experiences across pharmaceutical Julie Barret-Major, Director of Intellectual Property, Norgine
industry
• How the Biotech Company Strategies fit to these changes 2. 50 Afternoon Tea
Sakir Mutevelic, Head of Global Project Management
Biopharmaceuticals Hemophilia A / VWD, Baxter 3.30 EU Pharmaceutical Sector Inquiry and Antitrust Enforcement:
Michael O'Grady, Portfolio-Analysis Manager, GlaxoSmithKline • Main findings
Arif Shivji, World Wide Business Development Senior Manager, Pfizer • Policy recommendations
Marie Bernasconi, Global Program Team Director, Novartis • Antitrust enforcement
Fabio Domanico, Case Handler, European Pharmaceuticals Sector Task
10.30 Morning Coffee Force, DG Competition – European Commission
10.50 New approaches towards managing a portfolio of innovation projects
4.10 An update on data protection developments :
• Innovation management at Merck Serono
• The global marketing authorization (MA) regarding various
• Cross-divisional idea competition
holders of MAs
• Using new web2.0 tools
• The global MA regarding racemate/enantiomer :
• Fostering innovativeness and entrepreneurial thinking
citalopram/escitalopram and zopiclone/eszopiclone cases
Ulrich Betz, Director, Department Head Center of Innovation, Merck
• What about the data protection of a new generation of a biologic
Serono
product ?
11.30 Creating and challenging LCM brand plans • The reference product
• Selecting and implementing sustainable LCM strategies Elisabeth Berthet, Lawyer at the Paris Bar, Armengaud-Guerlain
• Combining LCM strategies for maximum effectiveness
• Credibility / robustness tests for LCM brand plans 4.40 Chairman’s Closing Remarks and Close of Day Two
Tony Ellery, President, Ellery Pharma Consulting, Former Global Head Tony Ellery, President, Ellery Pharma Consulting, Former Global Head
LCM in Portfolio Management, Novartis LCM in Portfolio Management, Novartis
x your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
ABOUT THE SMi PHARMACEUTICAL TEAM SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi have been involved in the pharmaceutical industry since 1993 and have SMi offer sponsorship, exhibition, advertising and branding packages,
uniquely tailored to complement your company’s marketing strategy.
developed a series of informative and niche events, covering the latest Prime networking opportunities exist to entertain, enhance and expand
issues and developments surrounding the industry. Events bring together your client base within the context of an independent discussion specific
senior industry professionals and serving companies who have a focus on to your industry. Should you wish to join the increasing number of
being at the forefront of developments in this area. SMi aim to generate companies benefiting from sponsoring our conferences please call: Alia
informed and topical discussion through the medium of both conferences Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
and executive briefings. Our pharmaceutical events are research-based and
Want to know how you can get involved?
content driven with regular contact with major industry personnel and cover Interested in promoting your pharmaceutical services to this market?
a wide range of industry sectors. For more information, please visit
www.smi-online.co.uk/pharma.asp Contact Jennifer Ireland, SMi Marketing on +44 (0)20 7827 6132,
or email: jireland@smi-online.co.uk

4. HALF DAY PRE-CONFERENCE WORKSHOP
Tuesday 28th June 2011
1.30pm-5.30pm
Holiday Inn Bloomsbury, London
Tools and Techniques for Optimal Drug
Development Portfolio Planning: Portfolio
Selection, Resource Allocation, and Risk
Mitigation
In association with
Overview of Workshop
Portfolio planning is crucial for developing long-term
company strategy. The goal is to select the “best” portfolio
of internal and external drug development programs for
funding and to align company strategy with available
resources such as money, manpower and manufacturing
capacity, in order to mitigate portfolio risk. Building
strategic risk scenarios into portfolio planning can buffer
the organization against the unexpected. Examples might
be clinical trial failure, shifts in the marketplace or
insufficient resource capacity. How to build in strategic risk
into long-term portfolio planning? How to align portfolio
value, resources and risk? How to protect your profits
against unexpected events? How to simulate and analyze
variety of risk mitigation strategies? This workshop covers
various portfolio planning tools and techniques with a
focus on strategic risk management.
1.30 Registration
2.00 Welcome & Introductions
2.10 Optimization of strategic portfolio planning
• Technique overview
• Components of portfolio optimization tool
- Projects value – qualitative, quantitative
(rNPV)
- Resources – money, manpower
- Business rules and strategic goals
• Portfolio scenarios
- Modification of strategic goals
- Bottleneck analysis
- Contingency planning
2.45 Risk and uncertainty in portfolio planning
• Strategic and operational risk
• Risk assessment techniques
• Flaw of averages
3.45 Afternoon Tea
4.00 Portfolio simulation for risk assessment and
analysis of risk mitigation strategies
• Workflow modelling
• Portfolio simulation/animation
• Portfolio value vs. risk
• Analysis of risk mitigation strategies
- Contingency planning
- Growth options/secondary indications
- Reformulation (new tricks for old drugs)
- In- out-licensing
5.00 Discussion Session
5.30 Close of Workshop
About the workshop host
Vladimir Shnaydman, Ph.D, is President of
ORBee Consulting. Worked for Biogen Idec for
several years, managing Biogen portfolio.
Vladimir has BS & MS Electrical Engineering &
Computer Science, MS in Applied Mathematics
& Operations Research, and Ph.D. in
Engineering. He contributed to many industries such as
biotechnology, computer networking, data storages, water
resources planning and management,
telecommunications, transportation, and others. Dr.
Shnaydman published more than 50 papers. He is co-
author of three books.

5. PHARMACEUTICAL
FORWARD PLANNER
February 2011
02/03 Adaptive Designs in Clinical Drug
Development
07/08 Parallel Trade
21/22 Advances and Progress in Drug Design
23/24 Stem Cells
March 2011
07/08 Imaging in Cancer Drug Development
14/15 Pharmacovigilance
16/17 Superbugs & Superdrugs
23/24 Accelerating patient recruitment &
Retention in Clinical Trials
30/31 Controlled Release
April 2011
13/14 Asthma & COPD
May 2011
11/12 Generics, Supergenerics and Patent
Strategies
16/17 Clinical Trial Logistics
June 2011
01/02 Pain Therapeutics
27/28 RNAi
29/30 Nanotechnology
29/30 Pharmaceutical Portfolio & Product
Lifecycle Management
29/30 KOL Europe (Munich, Germany)
July 2011
06/07 ADMET
11/12 BioBanking
11/12 Social Media in the Pharmaceutical
Industry
18/19 Clinical Trial Logistics Asia (Singapore)
20/21 Pre-Filled Syringes Asia (Singapore)
All conferences take place in central London, UK
– unless indicated otherwise in brackets
ABOUT THE SMi PHARMACEUTICAL TEAM
SMi have been involved in the pharmaceutical
industry since 1993 and have developed a series of
informative and niche events, covering the latest
issues and developments surrounding the industry.
Events bring together senior industry professionals
and serving companies who have a focus on being at
the forefront of developments in this area. SMi aim to
generate informed and topical discussion through the
medium of both conferences and executive briefings.
Our pharmaceutical events are research-based and
content driven with regular contact with major
industry personnel and cover a wide range of industry
sectors. For more information, please visit www.smi-
online.co.uk/pharma

6. PHARMACEUTICAL PORTFOLIO & PRODUCT LIFE-CYCLE MANAGEMENT
Conference: Wednesday 29th – Thursday 30th June 2011, Holiday Inn Bloomsbury, London, UK Workshop: Tuesday 28th June 2011, London
4 WAYS TO REGISTER
www.pharma-portfolio.com
FAX your booking form to +44 (0) 870 9090 712 POST your booking form to: Events Team, SMi Group Ltd, Great Guildford
PHONE on +44 (0) 870 9090 711 Business Square, 30 Great Guildford Street London, SE1 0HS, UK
EARLY BIRD □ Register by 28th February and Receive a £300 Discount
DISCOUNT □ Register by 31st March and Receive a £100 Discount
CONFERENCE PRICES
I would like to attend: (Please tick as appropriate) Fee Total
□ Conference & Half-Day Workshop £1998.00 +VAT £2397.60
□ Conference only £1399.00 + VAT £1678.80
Unique Reference Number □ Half-Day Workshop £599.00 + VAT £718.80
Our Reference LVY19 PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
DELEGATE DETAILS literature to all conference attendees £999.00 + VAT £1198.80
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename: GROUP DISCOUNTS AVAILABLE
Surname:
The Conference fee includes refreshments, lunch, conference papers and
Job Title:
CD ROM containing all of the presentations.
Department/Division:
Company/Organisation:
Email:
VENUE Holiday Inn, London - Bloomsbury, Coram Street, London WC1N 1HT, London, UK
Address: □ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
Town/City:
Post/Zip Code: Country:
CD ROMS/DOCUMENTATION
Direct Tel: Direct Fax:
I cannot attend but would like to purchase the following CD ROMs:
Mobile:
(Shipped 10-14 days after the event) Price Total
Switchboard: □ Conference presentations on CD ROM (Slides only) £499.00 +VAT £598.80
□ The conference presentations – paper copy £499.00 - £499.00
Signature: Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
ACCOUNTS DEPT PAYMENT
Title: Forename:
Payment must be made to SMi Group Ltd, and received before the event, by one of the
Surname: following methods quoting reference Y19 and the delegate’s name. Bookings made within 7
days of the event require payment on booking, methods of payment are below. Please
Email: indicate method of payment:
Address (if different from above):
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
Town/City:
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
Post/Zip Code: Country: □ Credit Card □ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
Direct Tel: Direct Fax:
Card No: □□□□ □□□□ □□□□ □□□□
Terms and Conditions of Booking Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit card
details will be requested and payment taken before entry to the event. Bookings within 7 days of
event require payment on booking. CD Roms will not be dispatched until payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another Cardholder’s Name:
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Signature: Date:
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a I agree to be bound by SMi's Terms and Conditions of Booking.
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the Card Billing Address (If different from above):
Conference documentation on CD ROM to any delegate who has paid but is unable to attend for any
reason. Due to the interactive nature of the Briefings we are not normally able to provide
documentation in these circumstances. We cannot accept cancellations of orders placed for
Documentation or CD ROM as these are reproduced specifically to order. If we have to cancel the
event for any reason, then we will make a full refund immediately, but disclaim any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □ we may also share your data with third parties
VAT
offering complementary products or services. If you have any queries or want to update any of the
data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on CD
or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your ROMs and Literature Distribution for all UK customers and for those EU customers not
address on the attached letter.
supplying a registration number for their own country here: _______________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk